Fig. 6: The clinical prognostic value of TMEM170B in breast cancer | Cell Death & Disease

Fig. 6: The clinical prognostic value of TMEM170B in breast cancer

From: Transmembrane protein 170B is a novel breast tumorigenesis suppressor gene that inhibits the Wnt/β-catenin pathway

Fig. 6

TMEM170B (a) or β-catenin (b) levels in clinical breast cancer tissues and noncancer tissues. Scale bar represents 50 µm (left) or 20 µm (right). The correlation of (c) TMEM170B and β-catenin expression in clinical breast cancer tissues. d, e Kaplan–Meier analysis of the overall survival in the clinical BRCA patients with different TMEM170B (d), β-catenin (e) expression, or TMEM170B/β-catenin expression patterns (f). A proposed model (g) of TMEM170B functions in the Wnt pathway in breast cancer progression. TMEM170B inhibits β-catenin stabilization and nucleus translocation, which reduces the activity of Wnt targets and inhibits the breast cancer proliferation and metastasis. Values are shown as mean ± S.E.M. *P < 0.05 vs. CTRL, **P < 0.01 vs. CTRL, ***P < 0.001 vs. CTRL

Back to article page